Literature DB >> 12446476

Diagnostic accuracy of alpha(1)-acid glycoprotein fucosylation for liver cirrhosis in patients undergoing hepatic biopsy.

Ingvar Rydén1, Peter Påhlsson, Stefan Lindgren.   

Abstract

BACKGROUND: Increased fucosylation of serum glycoproteins has previously been reported in patients with liver disease. We analyzed alpha(1)-acid glycoprotein (AGP) fucosylation in serum samples from patients investigated for suspected liver disease to evaluate its value as a biochemical marker for liver cirrhosis.
METHODS: We used a novel lectin immunoassay adapted to the AutoDELFIA system to analyze AGP fucosylation in 261 consecutive patients admitted for liver biopsy at Malmö University Hospital in Southern Sweden. The results were compared with histopathologic findings. In addition, AGP fucosylation was compared with other biochemical markers described as useful in the diagnosis of liver cirrhosis. The biochemical markers were compared by ROC curve analysis.
RESULTS: AGP fucosylation was significantly (P <0.05) higher in patients with liver cirrhosis (n = 65) than in healthy controls (n = 72), patients with normal histology (n = 29), patients with steatosis only (n = 38), patients with viral or chronic hepatitis without cirrhosis (n = 71), and patients with other liver diseases without histologic signs of cirrhosis (n = 58). By calculating the AGP fucosylation index (AGP-FI = AGP fucosylation/AGP serum concentration), we obtained a high diagnostic accuracy. The areas under the ROC curves for AGP-FI were 0.83 and 0.74 for men and women, respectively, compared with 0.82 for hyaluronic acid and 0.77 for the aspartate aminotransferase/alanine aminotransferase ratio in both men and women.
CONCLUSIONS: AGP fucosylation appears to be useful in identifying patients with liver cirrhosis among patients investigated for liver disease. The lectin immunoassay showed satisfactory reproducibility and is suitable for routine use in a clinical laboratory.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12446476

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  6 in total

1.  Glycoproteomic probes for fluorescent imaging of fucosylated glycans in vivo.

Authors:  Masaaki Sawa; Tsui-Ling Hsu; Takeshi Itoh; Masakazu Sugiyama; Sarah R Hanson; Peter K Vogt; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-08       Impact factor: 11.205

2.  N-glycans in liver-secreted and immunoglogulin-derived protein fractions.

Authors:  S Bekesova; O Kosti; K B Chandler; J Wu; H L Madej; K C Brown; V Simonyan; R Goldman
Journal:  J Proteomics       Date:  2012-02-03       Impact factor: 4.044

3.  Detection of a high affinity binding site in recombinant Aleuria aurantia lectin.

Authors:  Johan Olausson; Lena Tibell; Bengt-Harald Jonsson; Peter Påhlsson
Journal:  Glycoconj J       Date:  2008-05-21       Impact factor: 2.916

4.  Systems Analysis of the Complement-Induced Priming Phase of Liver Regeneration.

Authors:  Jun S Min; Robert A DeAngelis; Edimara S Reis; Shakti Gupta; Mano R Maurya; Charles Evans; Arun Das; Charles Burant; John D Lambris; Shankar Subramaniam
Journal:  J Immunol       Date:  2016-08-10       Impact factor: 5.422

Review 5.  Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry.

Authors:  Jose L Luque-Garcia; Thomas A Neubert
Journal:  J Chromatogr A       Date:  2006-12-12       Impact factor: 4.759

6.  Orosomucoid in liver diseases.

Authors:  Gulsum Ozlem Elpek
Journal:  World J Gastroenterol       Date:  2021-12-07       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.